Since its overexpression has been described in BRCA1-deficient mouse mammary tumors [160,161], researchers investigated whether EZH2 was essential for cancer cell survival or a tumorigenic byproduct, demonstrating an EZH2-dependence, while BRCA1-intact cells tolerate EZH2 loss. This evidence concerns the gene BRCA1 and cancer.